Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Terminated 2Withdrawn 1

Sponsor Class

OTHER 8INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Bone Cysts 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Steroids × Clear all
NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma

NCT03104270 2022-03-31

Combination Study for High Risk Multiple Myeloma Patients

Oncotherapeutics

Phase 2 Terminated
13 enrolled
Plasma cell

Multiple Myeloma

NCT00459641 2012-07-17

Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts

Kuros Biosurgery AG

Phase 2 Withdrawn

Bone Cysts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡